Header Logo

Connection

JULIE GASTIER-FOSTER to Imatinib Mesylate

Back to Details
This is a "connection" page, showing publications JULIE GASTIER-FOSTER has written about Imatinib Mesylate.
JULIE GASTIER-FOSTER
Connection Strength
0.052
Imatinib Mesylate
  1. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023 Jul; 10(7):e510-e520.
    View in: PubMed
    Score: 0.052
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.